Bibliographic Details
| Title: |
Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case–control study. |
| Authors: |
Munter, Leonie de, Meeraus, Wilhelmine, Dwivedi, Akshat, Mitratza, Marianna, Wyndham-Thomas, Chloé, Carty, Lucy, Ouwens, Mario, Hartig-Merkel, Wendy, Drikite, Laura, Rebry, Griet, Casas, Irma, Mira-Iglesias, Ainara, Icardi, Giancarlo, Otero-Romero, Susana, Baumgartner, Sebastian, Martin, Charlotte, Holemans, Xavier, Kate, Gerrit Luit ten, Bollaerts, Kaatje, Taylor, Sylvia |
| Source: |
European Journal of Public Health; Apr2025, Vol. 35 Issue 2, p373-378, 6p |
| Subject Terms: |
RESEARCH funding, HOSPITAL care, VACCINE effectiveness, COVID-19 vaccines, DESCRIPTIVE statistics, CASE-control method, CONFIDENCE intervals, COVID-19, EVALUATION |
| Geographic Terms: |
ITALY, AUSTRIA, SPAIN, BELGIUM, EUROPE |
| Abstract: |
Marketing authorization holders of vaccines typically need to report brand-specific vaccine effectiveness (VE) to the regulatory authorities as part of their regulatory obligations. COVIDRIVE (now id. DRIVE) is a European public–private partnership for respiratory pathogen surveillance and studies of brand-specific VE with long-term follow-up. We report the final VE results from a two-dose primary series AZD1222 (ChAdOx1 nCoV-19) vaccine schedule in ≥18-year-old individuals not receiving boosters. Patients (N = 1,333) hospitalized with severe acute respiratory infection at 14 hospitals in Austria, Belgium, Italy, and Spain were included in the test-negative case–control study in 2021–2023. Absolute VE was calculated using generalized additive model (GAM), generalized estimating equation (GEE), and spline-based area under the curve (AUC, measuring VE up to 6 months after the last dose of AZD1222). Overall VE (against coronavirus disease 2019 [COVID-19] hospitalization) of an AZD1222 primary series was estimated as 65% using GEE (95% confidence interval [CI]: 52.9–74.5), and 69% using GAM (95% CI: 50.1–80.9) over the 22-month study period (comparator group: unvaccinated patients). The AUC of the spline-based VE estimate was 74.1% (95% CI: 60.0–88.3). VE against hospitalization in study participants who received their second AZD1222 dose 2 months or less before hospitalization was 86% using GEE (95% CI: 77.8–91.4), 93% using GAM (95% CI: 67.2–98.6). During this study period, where mainly the severe acute respiratory syndrome coronavirus 2 Omicron variant was circulating, a two-dose primary series AZD1222 vaccination conferred protection against COVID-19 hospitalization up to at least 6 months after the last dose. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Public Health is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
